These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

320 related items for PubMed ID: 20005409

  • 1. Bortezomib successfully reverses early recurrence of light-chain deposition disease in a renal allograft: a case report.
    Kaposztas Z, Kahan BD, Katz SM, Van Buren CT, Cherem L.
    Transplant Proc; 2009 Dec; 41(10):4407-10. PubMed ID: 20005409
    [Abstract] [Full Text] [Related]

  • 2. [Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of literature].
    Adam Z, Krejcí M, Pour L, Stepánková S, Cermáková Z, Voska L, Teplan V, Krivanová A, Hájek R, Mayer J.
    Vnitr Lek; 2009 Nov; 55(11):1089-96. PubMed ID: 20017442
    [Abstract] [Full Text] [Related]

  • 3. Treatment of multiple myeloma: 2009 update.
    Prescrire Int; 2009 Dec; 18(104):263-6. PubMed ID: 20025098
    [Abstract] [Full Text] [Related]

  • 4. Bortezomib-dexamethasone combination in a patient with refractory multiple myeloma and impaired renal function.
    Nozza A, Siracusano L, Armando S.
    Clin Ther; 2006 Jun; 28(6):953-9. PubMed ID: 16860177
    [Abstract] [Full Text] [Related]

  • 5. "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.
    Gasparetto C, Gockerman JP, Diehl LF, de Castro CM, Moore JO, Long GD, Horwitz ME, Keogh G, Chute JP, Sullivan KM, Neuwirth R, Davis PH, Sutton LM, Anderson RD, Chao NJ, Rizzieri D.
    Biol Blood Marrow Transplant; 2010 Jan; 16(1):70-7. PubMed ID: 19733251
    [Abstract] [Full Text] [Related]

  • 6. Bortezomib in the front-line treatment of multiple myeloma.
    Richardson PG, Mitsiades C, Schlossman R, Ghobrial I, Hideshima T, Munshi N, Anderson KC.
    Expert Rev Anticancer Ther; 2008 Jul; 8(7):1053-72. PubMed ID: 18588451
    [Abstract] [Full Text] [Related]

  • 7. Long-term outcome of autologous stem cell transplantation in light chain deposition disease.
    Lorenz EC, Gertz MA, Fervenza FC, Dispenzieri A, Lacy MQ, Hayman SR, Gastineau DA, Leung N.
    Nephrol Dial Transplant; 2008 Jun; 23(6):2052-7. PubMed ID: 18178602
    [Abstract] [Full Text] [Related]

  • 8. [Bortezomib plus dexamethasone treatment followed by reduced-intensity allogeneic stem cell transplantation for multiple myeloma refractory to high-dose chemotherapy with autologous transplantation].
    Hayashi T, Yasui H, Kawakami K, Ikeda H, Takahashi F, Kobayashi T, Nishimura S, Ishida T, Imai K, Shinomura Y.
    Rinsho Ketsueki; 2011 Mar; 52(3):136-41. PubMed ID: 21471701
    [Abstract] [Full Text] [Related]

  • 9. Bortezomib/dexamethasone followed by autologous stem cell transplantation as front line treatment for light-chain deposition disease.
    Tovar N, Cibeira MT, Rosiñol L, Solé M, de Larrea CF, Escoda L, Rovira M, Bladé J.
    Eur J Haematol; 2012 Oct; 89(4):340-4. PubMed ID: 22690902
    [Abstract] [Full Text] [Related]

  • 10. Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma.
    Vogl DT, Stadtmauer EA, Richardson PG, Sonneveld P, Schuster MW, Irwin D, Facon T, Harousseau JL, Boral A, Neuwirth R, Anderson KC.
    Br J Haematol; 2009 Nov; 147(4):531-4. PubMed ID: 19725827
    [Abstract] [Full Text] [Related]

  • 11. Management of multiple myeloma with bortezomib: experts review the data and debate the issues.
    Dicato M, Boccadoro M, Cavenagh J, Harousseau JL, Ludwig H, San Miguel J, Sonneveld P.
    Oncology; 2006 Nov; 70(6):474-82. PubMed ID: 17283449
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors.
    Dimopoulos MA, Roussou M, Gavriatopoulou M, Zagouri F, Migkou M, Matsouka C, Barbarousi D, Christoulas D, Primenou E, Grapsa I, Terpos E, Kastritis E.
    Clin Lymphoma Myeloma; 2009 Aug; 9(4):302-6. PubMed ID: 19717380
    [Abstract] [Full Text] [Related]

  • 14. Bortezomib treatment followed by a second non-myeloablative allogeneic stem cell transplant in two previously autografted patients with multiple myeloma relapse.
    Mattei D, Mordini N, Vigna Taglianti R, Bruno B, Rapezzi D, Gallamini A.
    Haematologica; 2005 Jun; 90(6):861-2. PubMed ID: 15951306
    [Abstract] [Full Text] [Related]

  • 15. Bortezomib in combination with conventional chemotherapeutic agents for multiple myeloma compared with bortezomib alone.
    Min CK, Lee MJ, Eom KS, Lee S, Lee JW, Min WS, Kim CC, Kim M, Lim J, Kim Y, Han K.
    Jpn J Clin Oncol; 2007 Dec; 37(12):961-8. PubMed ID: 18156171
    [Abstract] [Full Text] [Related]

  • 16. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
    Eom HS, Min CK, Cho BS, Lee S, Lee JW, Min WS, Kim CC, Kim M, Kim Y.
    Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
    [Abstract] [Full Text] [Related]

  • 17. [Treatment with a proteasome inhibitor, bortezomib, for thalidomide-resistant multiple myeloma].
    Takatoku M, Noborio-Hatano K, Takahashi S, Kikuchi S, Mori M, Muroi K, Komatsu N, Ozawa K.
    Rinsho Ketsueki; 2004 Feb; 45(2):144-8. PubMed ID: 15045823
    [Abstract] [Full Text] [Related]

  • 18. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
    Badros A, Goloubeva O, Dalal JS, Can I, Thompson J, Rapoport AP, Heyman M, Akpek G, Fenton RG.
    Cancer; 2007 Sep 01; 110(5):1042-9. PubMed ID: 17654660
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Outcome of bortezomib plus chemotherapy with or without stem cell transplantation for treatment of multiple myeloma].
    Wang YF, Deng SH, Wu T, Xu Y, Zou DH, Wang Y, Zhao YZ, Qiu LG.
    Zhonghua Xue Ye Xue Za Zhi; 2008 Jun 01; 29(6):397-400. PubMed ID: 19031743
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.